Seeking Alpha

Eli Lilly (LLY +0.1%) CEO John Lechleiter tells NYT in a lengthy profile that "we're trying to...

Eli Lilly (LLY +0.1%) CEO John Lechleiter tells NYT in a lengthy profile that "we're trying to be realistic while maintaining our optimism," but the drug maker is losing patent protection in the next seven years on drugs that accounted for 74% of its sales in 2009, a decline considered to be the worst patent cliff facing major companies in the industry.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs